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Abstract
Background
Tuberculous pericardial effusion is a pro-fibrotic condition that is complicated by constrictive
pericarditis in 4% to 8% of cases. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a ubiq-
uitous tetrapeptide with anti-fibrotic properties that is low in tuberculous pericardial effusion,
thus providing a potential mechanism for the heightened fibrotic state. Angiotensin-convert-
ing enzyme inhibitors (ACE-I), which increase Ac-SDKP levels with anti-fibrotic effects in
animal models, are candidate drugs for preventing constrictive pericarditis if they can be
shown to have similar effects on Ac-SDKP and fibrosis in human tissues.
Objective
To systematically review the effects of ACE-Is on Ac-SDKP levels in human tissues.
Methods
We searched five electronic databases (1996 to 2014) and conference abstracts with no
language restrictions. Two reviewers independently selected studies, extracted data and
assessed methodological quality. The protocol was registered in PROSPERO.
Results
Four studies with a total of 206 participants met the inclusion criteria. Three studies (106
participants) assessed the change in plasma levels of Ac-SDKP following ACE-I administra-
tion in healthy humans. The administration of an ACE-I was associated with an increase in
Ac-SDKP levels (mean difference (MD) 5.07 pmol/ml (95% confidence intervals (CI) 0.64
pmol/ml to 9.51 pmol/ml)). Two studies with 100 participants further assessed the change in
Ac-SDKP level in humans with renal failure using ACE-I. The administration of an ACE-I
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was associated with a significant increase in Ac-SDKP levels (MD 8.94 pmol/ml; 95% CI
2.55 to 15.33; I2 = 44%).
Conclusion
ACE-I increased Ac-SDKP levels in human plasma. These findings provide the rationale for
testing the impact of ACE-I on Ac-SDKP levels and fibrosis in tuberculous pericarditis.
Introduction
Tuberculous pericarditis is an important cause of heart failure in sub-Saharan Africa and other
developing regions of the world where tuberculosis is endemic[1,2]. Constrictive pericarditis is
a serious complication that occurs in 4–6% of cases of tuberculous pericarditis despite treat-
ment with anti-tuberculous drugs and adjunctive corticosteroids[3]. Mutyaba and others inves-
tigated the causes of constrictive pericarditis, outcomes after pericardiectomy, and predictors
of mortality in Cape Town, South Africa, during a 22-year period of high HIV/AIDS preva-
lence [4]. They found that TB was the main cause of constrictive pericarditis in South Africa,
and that despite its efficacy at relieving the symptoms of heart failure, pericardiectomy was
associated with high perioperative mortality of 16% that was not influenced by HIV status.
New York Heart Association Functional Class IV and hyponatremia were predictors of early
mortality after pericardiectomy [4]. TB pericarditis is associated with decreased levels of the
anti-fibrotic tetrapeptide N-acetylseryl-aspartyl-lysyl-proline (Ac-SDKP) [5], whereas ACE-I’s
are known to increase Ac-SDKP levels in rodent tissues [6]. Ac-SDKP is a potent anti-fibrotic
agent and a negative regulator of hematopoietic stem cell differentiation. If ACE-I’s increase
Ac-SDKP levels in human tissues, then they would be candidate drugs for use in TB pericarditis
to prevent fibrosis and constriction[7,8] We conducted a systematic review of the literature to
determine whether ACE-I’s increase Ac-SDKP levels in human tissues.
Methods
The methods used were based on our protocol, which was registered in Prospero [9].
Search Strategy
Two authors (ATM and MEE) undertook a systematic literature search of a number of data-
bases for studies on the effects of ACE-I on human Ac-SDKP levels. Potentially relevant studies
were selected on the basis of title and abstract for scrutiny without language restriction. The fol-
lowing databases where searched: PubMed, Google Scholar, EMBASE and the Cochrane
Library. A combination of the following search terms (including the use of MeSH) was used:
angiotensin-converting enzyme, angiotensin-converting enzyme inhibitors, human, N-acetyl-
seryl-aspartyl-lysyl-proline, and Ac-SDKP. The search strategy is outlined in Table 1. The ref-
erence lists of identified articles were reviewed. Authors and experts undertaking research in
the field of ACE-I and Ac-SDKP were also consulted. Studies selected for review were prospec-
tive observational studies of the effects of ACE-I on human Ac-SDKP levels.
Table 1. Pubmed search strategy (adapted for use in other databases).
#1 ("angiotensin converting enzyme inhibitors" OR "ACE inhibitors")
#2 ("N-acetyl-seryl-aspartyl-lysyl-proline level" OR Ac-SDKP level)
#3 (#1 AND #2) Filters: Humans
doi:10.1371/journal.pone.0143338.t001
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Criteria for considering studies for this review
Types of studies. All prospective and observational studies were included.
Types of participants. Only studies with human participants were included.
Types of interventions. Interventions had to include any ACE-I, whether alone or as part
of other interventions. Control intervention was any placebo.
Types of outcome measures. The primary outcome was the change in Ac-SDKP levels as
detected by standardised laboratory assays/protocols following ACE-I administration in
humans.
Data Extraction and Management
Data were extracted by two authors (ATM and MEE) using a standardised data extraction
form. Data were entered into Review Manager 5.1 statistical software for meta-analysis. Any
disagreements on the eligibility of articles for inclusion were discussed with BMM.
Quality Assessment
All articles included were critically appraised by two authors (ATM and MEE) for methodolog-
ical quality in accordance with the methods of the Cochrane Collaboration[10]. Each article
included was assessed for risk of bias based on sequence generation, allocation concealment,
blinding, and incomplete outcome or missing data, where applicable. Heterogeneity between
studies was assessed using the chi-square test set at a 10% level of significance[10]. The impact
of any statistical heterogeneity was quantified using the I² statistic. If there was an acceptable
degree of heterogeneity and it was appropriate to pool the data, the Mantel-Haenszel statistical
method and Random Effects Analysis Model were used, with the results presented in the form
of a meta-analysis.
Data Synthesis and Analysis
Two authors (ATM and MSB) reviewed all the relevant articles identified from the search and,
after scanning the titles, identified those that could potentially be included, subject to a reading
of the abstracts. The full text of the articles was obtained for final evaluation for inclusion into
the review according to the pre-specified inclusion criteria. The PRISMA guideline was used in
reporting the findings of this review (S1 Text) [11]. The outcome (i.e. the effect of ACE-I on
the Ac-SDKP level) was considered as a continuous variable. The outcome measure was calcu-
lated using risk ratios and 95% confidence intervals. Outcomes expressed in ng/ml were con-
verted to pmol/ml by dividing the ng/ml value by the molecular weight of Ac-SDKP (487
Daltons) X 10−3. Interquartile ranges were converted to standard deviations as recommended
in the Cochrane Handbook.[10]
Results
Seventy-four papers where identified by the electronic search, of which 55 were excluded based
on title and abstract (Fig 1). A further 15 papers were excluded following a full review of the
text, as they were animal studies (n = 8) or not related to the primary outcome (n = 7). Thus,
four studies met the inclusion criteria (Azizi 1996, Azizi 1997, Azizi 1999, Inoue 2010). The
studies included were conducted in France (Azizi 1996, Azizi 1997, Azizi 1999) and in Japan
(Inoue 2010). The studies in France included healthy subjects (Azizi 1996), patients with
hypertension (Azizi 1997) and patients with renal failure (Azizi 1999). The study in Japan
(Inoue 2010) included a combination of healthy patients and those with renal failure. The
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included studies are described in Table 2. The reasons for excluding studies that were initially
considered relevant are provided in Table 3.
Change in Ac-SDKP levels in healthy participants
Three studies (106 participants) assessed the change in the levels of Ac-SDKP following ACE-I
administration in healthy humans [12,13,14]. Given the high statistical heterogeneity between
studies (I2 = 81%), a random-effects model was used. The administration of an ACE-I was asso-
ciated with an increase in Ac-SDKP levels (mean difference (MD), 5.07 pmol/ml (95% confi-
dence intervals (CI) 0.64 pmol/ml to 9.51 pmol/ml) (Fig 2). After exclusion of the trial with a
small number of participants [12], the effect of ACE-I on Ac-SDKP levels remained significant,
with a mean difference of 2.62 pmol/ml (95% CI 0.93 to 4.31).
Change in Ac-SDKP levels in participants with renal failure
Two studies with 100 participants assessed the change in Ac-SDKP level in humans with renal
failure using ACE-I [15,28]. One study administered Captopril [28], while the second [15] used
Fig 1. Flow diagram of search results.
doi:10.1371/journal.pone.0143338.g001
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Table 2. Characteristic of studies included in the review.
Study
ID









16 healthy male Caucasian
volunteers, age range 20 to 35
years
Intervention: captopril (50 mg)
versus 50 ml of water (n = 8).
Control = 8 patients who received
placebo and 50 ml of water





Prospective cohort study set at
Broussais Hospital, Paris
50 white hypertensive patients
of both sexes aged 18 to 75
years
Varying dosages of ACE-I were
used;; 27 patients (21: M, 6: F) on
ACE-I. Age range: 58+/-12 years,
SBP: 164+/-33 mmHg; Control: 23
patients (17: M, 6: F) not on
ACE-I. Age range: 55+/-8 years;
SBP: 161+/-21 mmHg
Plasma Ac-SDKP levels elevated




Observational study set at
Broussais Clinical Investigation
Centre
32 patients on the single oral
dose; 12 patients on the
multiple oral doses; 58 patients
with CRF; 40 patients with
normal renal function
Single oral dose study: 32
patients; Captopril (50 mg) with
25 ml of water; Multiple oral dose
study: 12 patients; 10: Captopril
(50 mg) with 25 ml of water; 2:
placebo with 25 ml of water; 58
patients: 35 on ACE-I; 23 not on
ACE-I; 40 patients with normal
renal function: 19 on ACE-I; 21 not
on ACE-I
Renal failure was associated with a
slight increase in plasma Ac-SDKP
levels; Ac-SDKP levels were
increased in patients with normal
renal function treated with an
ACE-I,it was a moderate increase





Observational study set at
Meiyo Clinic, Japan
41 patients: 7 healthy, 34 on
dialysis; 28 dialysis patients: 10
on enalapril;; 18 on trandolapril
Existing patients on ACE-I–no
dosages stated
Study focused on relatively simple
and highly sensitive and specific
analytical method for the
quantitative determination of Ac-
SDKP and Ac-SDKP minor in
human plasma samples using SPE
and LC-MS/MS in the MRM mode
ACE-I, angiotensin-converting enzyme inhibitor; CRF, chronic renal failure; SBP, systolic blood pressure; LC-MS/MS, liquid chromatography-tandem mass
spectrometry; SPE, solid phase extraction; MRM, multiple reaction monitoring; Ac-SDKP minor, synthesised from thymosin β10
doi:10.1371/journal.pone.0143338.t002
Table 3. Characteristics of excluded studies.
Study ID Reason for exclusion
Bogden et al., 1991[7] Animal study
Cashman et al., 1994 [8] Animal study
Comte et al., 1998[16] Animal study
Struthers & MacFadyen, 1999[17] Not related to primary outcome
Azizi et al., 2000 [18] Not related to primary outcome
Azizi et al., 2001 [19] Not related to primary outcome
Peng et al. 2003 [20] Animal study
Cavasin et al., 2004[6] Not related to primary outcome
Rasoul et al., n.d.[21] Animal study
Azizi et al., 2006 [22] Units of measurement provided as a ratio (Ac-SDKP/Creatinine)
Cavasin et al., 2007 [23] Animal study
Lin et al., 2008[24] Animal study
Liu et al., 2009[25] Not related to primary outcome
Wang et al., 2010 [26] Animal study
Nakagawa et al., 2012 [27] Not related to primary outcome
doi:10.1371/journal.pone.0143338.t003
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two types of ACE-I, namely enalapril (10 patients) and trandolapril (18 patients). The adminis-
tration of an ACE-I was associated with a significant increase in Ac-SDKP levels (MD, 8.94
pmol/ml; 95% CI 2.55 to 15.33; I2 = 44%) (Fig 3). Unfortunately data was not available to allow
for comparison with mean baseline levels within the ACE-I group.
Methodological Quality
Table 4 shows the risk of bias assessment, which includes the components of random sequence
generation, allocation concealment, blinding of participants and personnel, blinding of out-
come assessment, incomplete data and selective outcome reporting. All these components were
assessed as being either low risk, high risk or unclear. There were no missing data in any of the
studies.
Discussion
This study has shown that ACE-I increases the plasma levels of Ac-SDKP in humans. This
effect is present in health and disease, and appears to be a class effect of ACE-I. These findings
are consistent with observations in animal models. However, no studies could be found on the
impact of ACE-I in other body tissues such as the pericardium, nor were there studies on the
effect of higher levels of Ac-SDKP on tissue fibrosis.
The hypothesis that treatment with ACE-I may increase the levels of Ac-SDKP in patients
with TB pericarditis, which was put forward by Ntsekhe and others[5], is supported by this
Fig 2. Change in Ac-SDKP levels in healthy participants. ACE-I, Angiotensin Converting Enzyme
Inhibitors; IV, inverse variance.
doi:10.1371/journal.pone.0143338.g002
Fig 3. Change in Ac-SDKP levels in participants with renal failure. ACE-I, Angiotensin Converting
Enzyme Inhibitors; IV, inverse variance.
doi:10.1371/journal.pone.0143338.g003
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study. Our findings open the way for experiments to determine whether ACE-I can safely
increase Ac-SDKP levels in pericardial fluid. However, the hypotensive effect of ACE-I may be
deleterious in patients with haemodynamic instability caused by TB pericarditis. ACE consists
of two catalytic domains–the C and N domains. The ‘C’ domain has a fivefold higher affinity
for angiotensin 1, which is responsible for the maintenance of blood pressure control [29,30].
The ‘N’ domain is responsible for the degradation of the tetrapeptide Ac-SDKP. The ‘N’
domain not only plays an essential role in the degradation of Ac-SDKP but also plays a signifi-
cant biological role, as is evident from a study that analysed bleomycin-induced lung injury in
ACE C domain knockout (ACEC-KO) mice and ACE N domain knock out (ACEN-KO) mice.
The ACEN-KO mice had significantly less bleomycin-induced lung fibrosis compared to
ACEC-KO mice. This study confirmed that the inhibition of the ‘N’ domain of ACE was associ-
ated with significant endogenous anti-fibrosis signalling in the lungs [31]. Therefore, an ‘N’
domain catalytic-specific ACE-I, such as RXP407, may have great potential as an anti-fibrotic
agent with minimal blood pressure effects in patients with haemodynamic instability such as
tuberculous pericarditis. The affinity of ACE-I for the ACE catalytic domain is structure depen-
dent. Zisman (1998)[32] was able to show that the hydrophobic moieties of ACE-I’s play an
essential role in domain selectivity. Captopril was the first ACE-I used clinically, and it exhib-
ited a threefold greater affinity for the ‘N’ domain than the ‘C’ domain. The newer ACE-I’s,
namely enalaprilat, lisinopril and trandolapril, which have been developed for their antihyper-
tensive properties, have been shown to display a higher affinity (approximately 24 times) for
the ‘C’ domain [33]. This may explain the disparity in the change in Ac-SDKP levels across the
studies using captopril compared to those using the newer ACE-I’s. The different dosages used
across the studies may also explain the disparity in the change in AcSDKP levels across the var-
ious studies. One study assessed the analytical method best suited for the validation of
AcSDKP. Mesmin et al used human urine and plasma to compare enzyme immuno assay and
liquid chromatography/tandem mass spectrometry. He was able to show that tandem mass
spectrometry, through the use of an internal standard, tailored sample preparation and chro-
matographic separation, had better intra- and inter-assay precision and allowed greater steadi-
ness in intra-subject concentrations during the infusion.[34]
The inclusion of four small studies with a total of 206 participants from France and Japan
may be seen as a limitation of this study. It is reassuring, however, that the direction of effect of
ACE-I on Ac-SDKP was consistent and followed the biological expectation. The findings there-
fore have both internal and external validity and are likely to be of general relevance.
Table 4. Risk of bias assessment.















Low risk Unclear Low risk Low risk Low risk Low risk
Azizi et al.
1997[13]
N/A High risk High risk High risk Low risk Low risk
Azizi et al.
1999[14]
N/A High risk High risk High risk Low risk Unclear
Inoue et al.
2010[15]
N/A High risk High risk High risk Unclear Unclear
N/A, not available.
doi:10.1371/journal.pone.0143338.t004
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Conclusion
ACE inhibition elevates Ac-SDKP levels in human plasma. These findings provide the rationale
for the testing of the effect of ACE-I on Ac-SDKP levels in pericardial fluid with a view to
reducing the incidence of constriction in tuberculous pericarditis.
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